MetaCap

Tempest Therapeutics (TPST) vs Exicure (XCUR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Exicure is the larger company by market cap ($5.9 million vs $5.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TPST-63.74%XCUR-11.75%
+23%-23%-68%
Oct 7, 20261 yearNov 20, 2026
TPST-62.24%XCUR-14.28%
+10%-28%-66%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TPST versus XCUR key metrics
MetricTPSTXCUR
Share price$0.287$0.9001
Market cap$5.74M$5.89M
1-day change-6.18%-12.82%
YTD return-90.00%—
1-year return-91.80%—
5-year return-99.77%—
EPS (TTM)$-3.16$-1.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-26.26M$-4.95M
52-week high$4.22$9.48
52-week low$0.28$0.777
Distance from 52-week high-93.20%-90.51%
Analyst consensusstrong_buy—
Avg. price target upside+2339.02%—
Average volume2.56M53.56K
Shares outstanding20.00M6.55M
Employees41
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Tempest Therapeutics

TPST stock →

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Exicure

XCUR stock →

Exicure, Inc. does not have significant operations.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

TPST vs XCUR FAQ

Which is bigger, Tempest Therapeutics or Exicure?

Exicure (XCUR) is larger, with a market capitalization of $5.89M compared with $5.74M for Tempest Therapeutics (TPST).

Are Tempest Therapeutics and Exicure in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons